ROCK CREEK PHARMACEUTICALS INC Inactive Instrument
Rock Creek Pharmaceuticals Inc Stock Nasdaq
Equities
US7720811055
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 2020 | Rock Creek Pharmaceuticals, Inc. Went Out of Business | CI |
| 2020 | Bankruptcy Judge Changed for Rock Creek Pharmaceuticals, Inc. | CI |
Financials (USD)
| Sales 2014 | - | Sales 2015 | - | Capitalization | 8.21M |
|---|---|---|---|---|---|
| Net income 2014 | -38M | Net income 2015 | -6M | EV / Sales 2014 | - |
| Net cash position 2014 | 45K | Net Debt 2015 | 19.86M | EV / Sales 2015 | - |
| P/E ratio 2014 |
-0.87
x | P/E ratio 2015 |
-1.04
x | Employees | - |
| Yield 2014 * |
-
| Yield 2015 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Talhia Tuck
IRC | Investor Relations Contact | 46 | 12-04-17 |
Rock Creek Pharmaceuticals Inc is a United States-based pharmaceutical development company. The Company is focused on the discovery, development and commercialization of therapies for chronic inflammatory disease and neurologic disorders. Its activities are focused on its lead compound, anatabine citrate (anatabine). Anatabine is a small molecule, cholinergic agonist, which exhibits anti-inflammatory pharmacological characteristics. The Company focuses on dermatological skin diseases, such as psoriasis, eczema and rare or orphan skin disorders, using its formulations of anatabine.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +25.61% | 660B | |
| +25.87% | 562B | |
| -5.24% | 358B | |
| +16.49% | 322B | |
| +8.28% | 297B | |
| +7.09% | 219B | |
| -9.12% | 196B | |
| +5.01% | 199B | |
| -8.75% | 149B |
